Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Esemo-Parmina | Healthcare Services | 28.3% | 88th pct | 268 |
| Total Sharm Vake | Healthcare Services | 18.0% | 74th pct | 268 |
| Tbilisis Tsentraluri La… | Healthcare Services | 10.6% | 53rd pct | 268 |
| Medical Vorld Diagnostik | Healthcare Services | 2.5% | 27th pct | 268 |
| Bi Parenti | Healthcare Services | -53.6% | 4th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Total Sharm Vake | Esemo-Parmina | Medical Vorld Diagnostik | Tbilisis Tsentraluri La… | Bi Parenti |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 48.3% | 78.0% | 80.1% | 38.8% | -19.0% |
| EBITDA Margin | 18.0% | 28.3% | 2.5% | 10.6% | -53.6% |
| EBITDAR | 557 | 884 | 223 | 318 | -1,450 |
| EBITDAR Margin | 18.0% | 28.9% | 7.4% | 10.6% | -50.2% |
| EBIT Margin | 8.9% | 25.9% | -2.0% | 10.6% | -53.9% |
| Net Profit Margin | 8.9% | 25.3% | 2.5% | 10.5% | -56.5% |
| Operating Expense % of Sales | 30.3% | 49.7% | 77.7% | 28.2% | 34.7% |
| Returns | |||||
| Return on Assets (ROA) | 10.7% | 19.0% | 1.9% | 34.1% | -87.7% |
| Return on Equity (ROE) | 10.8% | 20.9% | 2.5% | 118.4% | N/A |
| ROIC [EBIT / Invested Capital] | 11.9% | 21.8% | -2.0% | 120.9% | N/A |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | -0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | N/A |
| Equity-to-Assets | 99.5% | 90.9% | 75.1% | 28.8% | -76.9% |
| Net Debt | -237 | -54 | -64 | -4 | -106 |
| Cash & Equivalents | 237 | 54 | 64 | 4 | 106 |
| Total Debt | N/A | N/A | N/A | N/A | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 4.25x | 3.55x | 2.98x | 1.05x | 0.55x |
| Quick Ratio | 4.25x | 3.55x | 2.98x | 0.68x | 0.55x |
| Cash Ratio | 1.12x | 0.15x | 0.07x | 0.01x | 0.03x |
| Total Current Assets | 902 | 1,309 | 2,911 | 692 | 1,806 |
| Total Current Liabilities | 212 | 369 | 978 | 659 | 3,292 |
| Inventory | N/A | N/A | N/A | 244 | N/A |
| Trade Receivables | N/A | 1,110 | 1,686 | 444 | 1,651 |
| Trade Payables | N/A | 369 | 874 | N/A | 87 |
| Net Working Capital | 689 | 941 | 1,933 | 33 | -1,486 |
| Net Working Capital % of Revenue | 22.3% | 30.8% | 64.2% | 1.1% | -51.4% |
| Trade Working Capital | N/A | 741 | 812 | 688 | 1,564 |
| Trade Working Capital % of Revenue | N/A | 24.3% | 27.0% | 22.9% | 54.1% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | 7.52x | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | 48.6 | N/A |
| Receivables Turnover | N/A | 2.75x | 1.79x | 6.75x | 1.75x |
| Days Sales Outstanding (DSO) | N/A | 132.6 | 204.4 | 54.0 | 208.5 |
| Payables Turnover | N/A | 1.82x | 0.68x | N/A | 39.65x |
| Days Payable Outstanding (DPO) | N/A | 200.0 | 533.5 | N/A | 9.2 |
| Cash Conversion Cycle | N/A | -67.4 days | -329.1 days | 102.6 days | 199.3 days |
| Asset Turnover | 1.20x | 0.75x | 0.77x | 3.24x | 1.55x |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 55 | N/A | 706 | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | 55 | N/A | 623 | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | 6.3% | N/A | 222.0% | N/A |
| Dividends Declared | N/A | N/A | N/A | 600 | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | 189.9% | N/A |